Evidence map›Paper›PMID 39095528›Full record

ArticleBritish journal of cancer2024

Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis.

Lili Zhuo, Fanling Meng, Kaidi Sun, Meng Zhou, Jie Sun

Abstract read
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lili Zhuo *School of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China.
Fanling Meng *Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Kaidi SunDepartment of Gynecology, Harbin Medical University Cancer Hospital, Harbin, 150081, China.
Meng ZhouSchool of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China. zhoumeng@wmu.edu.cn.ORCID http://orcid.org/0000-0001-9987-9024
Jie SunSchool of Biomedical Engineering, Eye Hospital, Wenzhou Medical University, Wenzhou, 325027, China. suncarajie@wmu.edu.cn.ORCID http://orcid.org/0000-0002-0932-7195

Funding

National Natural Science Foundation of China (National Science Foundation of China) 62272346
6 · The paper itself

Abstract

backgroundOvarian cancer (OV) is a heterogeneous disease but has traditionally been treated as an immunologically cold malignancy. The relationship between the immune-active cancer phenotype typified by a T helper 1 (Th-1) immune response and clinical outcome in OV remains uncertain.

methodsA cohort-scale compendium of transcriptomic data from 2850 OV samples from 19 individual datasets was compiled for integrative immuno-transcriptomic analysis. The immunological constant of rejection was used as a metric to assess the Th-1/cytotoxic response orientation and investigate the clinical-biological significance of immune polarization towards a Th-1 immune response. Single-cell RNA sequencing data from 39 OV samples were analyzed to elucidate the variability of the immune microenvironment, and immunohistochemical validation was performed on 39 samples from the Harbin Medical University Cancer Hospital.

resultsOur results demonstrated the prognostic significance of a Th-1/cytotoxic immune profile within the tumor microenvironment (TME) using the immunological constant of rejection classification to OV samples. Specifically, patients with tumors expressing high levels of ICR markers showed significantly improved survival. A gene panel consisting of four chemokines (CXCL9, CXCL10, CXCL11 and CXCL13) was identified as critical players in mediating the establishment of an active T-cell-inflamed antitumor phenotype. This 4-chemokine signature, which was extensively validated in external multicenter cohorts through transcriptomic profiling and in an independent in-house cohort through immunohistochemistry, introduced a novel immune classification in OV and identified a chemokine-dominated subtype associated with an active antitumor immune phenotype and favorable prognosis. Single-cell transcriptomic analysis revealed that chemokine-dominated tumors increase CXCR3 + NK and T cell recruitment to the TME primarily through the overexpression of macrophage-derived CXCL9/10/11.

conclusionsThis study provides new insights into understanding immune heterogeneity within the TME and paves the way for tailoring appropriate therapeutic interventions for patients with differing immune profiles.

Indexed as

Chemokine CXCL11Gene Expression ProfilingOvarian NeoplasmsTumor MicroenvironmentBiomarkers, TumorChemokine CXCL10Chemokine CXCL13Chemokine CXCL9FemaleGene Expression Regulation, NeoplasticHumansPhenotypePrognosisSingle-Cell AnalysisTh1 CellsTranscriptomeBiomarkers, TumorChemokine CXCL10Chemokine CXCL11Chemokine CXCL13Chemokine CXCL9CXCL10 protein, humanCXCL11 protein, humanCXCL13 protein, humanCXCL9 protein, human

Identifiers

PMID39095528
PMCPMC11405890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.